The FDA approved Eli Lilly’s once-weekly basal insulin shot Onswik for patients with type 2 diabetes, giving the company a longer-acting option positioned as an alternative to daily basal injections. The approval sets up direct competitive pressure in the long-acting insulin market, including Novo Nordisk’s related efforts in the category. The approval was reported as part of a broader theme of regulators clearing more patient-convenience treatments, with weekly dosing designed to improve adherence and reduce injection burden. For development teams, the milestone increases the strategic importance of duration, pharmacokinetics and usability for chronic-care drugs. Competition in insulin has increasingly turned into a scheduling and regimen arms race—an area where manufacturing reliability and real-world dosing experience often decide market outcomes.